Tachedjian G, French M, Mills J
National Centre in HIV Virology Research, Macfarlane Burnet Centre for Medical Research, Fairfield, Victoria 3078, Australia.
Antimicrob Agents Chemother. 1998 Nov;42(11):3038-43. doi: 10.1128/AAC.42.11.3038.
Human immunodeficiency virus type 1 (HIV-1) isolates obtained from a patient with AIDS were assessed for coresistance to foscarnet and zidovudine. An HIV-1 strain (AP20) coresistant to foscarnet and zidovudine was isolated after 20 months of continuous combination therapy. The reverse transcriptase (RT) gene of AP20 had 41 substitutions which were different from the HXB2-D sequence and 9 that were different from the sequence of its foscarnet-sensitive, zidovudine-resistant progenitor virus (AP6). Six of these mutations were nonpolymorphic (T39A, V108I, K166R, K219R, K223Q, and L228R). Both strains had the conventional mutations mediating zidovudine resistance. In vivo selection may result in HIV-1 strains that are coresistant to foscarnet and zidovudine, but coresistance appears to require a complex evolutionary path and multiple RT mutations.
对从一名艾滋病患者身上获得的1型人类免疫缺陷病毒(HIV-1)分离株进行了膦甲酸钠和齐多夫定的交叉耐药性评估。在连续联合治疗20个月后,分离出了一株对膦甲酸钠和齐多夫定交叉耐药的HIV-1毒株(AP20)。AP20的逆转录酶(RT)基因有41个与HXB2-D序列不同的替换位点,以及9个与其对膦甲酸钠敏感、对齐多夫定耐药的亲代病毒(AP6)序列不同的位点。其中六个突变是非多态性的(T39A、V108I、K166R、K219R、K223Q和L228R)。两种毒株都有介导齐多夫定耐药性的传统突变。体内选择可能导致对膦甲酸钠和齐多夫定交叉耐药的HIV-1毒株,但交叉耐药似乎需要一条复杂的进化途径和多个RT突变。